1. Home
  2. CFFI vs CBIO Comparison

CFFI vs CBIO Comparison

Compare CFFI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CFFI
  • CBIO
  • Stock Information
  • Founded
  • CFFI 1927
  • CBIO 2003
  • Country
  • CFFI United States
  • CBIO United States
  • Employees
  • CFFI N/A
  • CBIO N/A
  • Industry
  • CFFI Major Banks
  • CBIO
  • Sector
  • CFFI Finance
  • CBIO
  • Exchange
  • CFFI Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • CFFI 218.0M
  • CBIO 208.8M
  • IPO Year
  • CFFI 1998
  • CBIO N/A
  • Fundamental
  • Price
  • CFFI $68.86
  • CBIO $12.82
  • Analyst Decision
  • CFFI
  • CBIO Strong Buy
  • Analyst Count
  • CFFI 0
  • CBIO 5
  • Target Price
  • CFFI N/A
  • CBIO $25.60
  • AVG Volume (30 Days)
  • CFFI 3.7K
  • CBIO 66.9K
  • Earning Date
  • CFFI 10-23-2025
  • CBIO 11-06-2025
  • Dividend Yield
  • CFFI 2.65%
  • CBIO N/A
  • EPS Growth
  • CFFI 43.03
  • CBIO N/A
  • EPS
  • CFFI 8.09
  • CBIO N/A
  • Revenue
  • CFFI $125,432,000.00
  • CBIO N/A
  • Revenue This Year
  • CFFI N/A
  • CBIO N/A
  • Revenue Next Year
  • CFFI N/A
  • CBIO N/A
  • P/E Ratio
  • CFFI $8.43
  • CBIO N/A
  • Revenue Growth
  • CFFI 9.28
  • CBIO N/A
  • 52 Week Low
  • CFFI $53.14
  • CBIO $9.81
  • 52 Week High
  • CFFI $89.90
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • CFFI 50.06
  • CBIO 53.98
  • Support Level
  • CFFI $66.48
  • CBIO $12.68
  • Resistance Level
  • CFFI $71.25
  • CBIO $13.50
  • Average True Range (ATR)
  • CFFI 1.19
  • CBIO 0.50
  • MACD
  • CFFI -0.18
  • CBIO 0.00
  • Stochastic Oscillator
  • CFFI 49.79
  • CBIO 63.33

About CFFI C&F Financial Corporation

C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: